Cargando…
A Blast From the Past: Abdominal Wall Amyloidosis Due to Enfuvirtide Injections
Enfuvirtide was the first marketed fusion inhibitor that worked by binding to glycoprotein 41 of the HIV envelope, preventing the conformational changes required for HIV fusion with CD4+ T cells. Due to its novel mechanisms of action, it was frequently used in the past as part of regimens for the in...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483575/ https://www.ncbi.nlm.nih.gov/pubmed/37692653 http://dx.doi.org/10.7759/cureus.43126 |
_version_ | 1785102416765517824 |
---|---|
author | Costiniuk, Cecilia Bourgault, Anne-Marie Maedler-Kron, Chelsea Feldman, Liane |
author_facet | Costiniuk, Cecilia Bourgault, Anne-Marie Maedler-Kron, Chelsea Feldman, Liane |
author_sort | Costiniuk, Cecilia |
collection | PubMed |
description | Enfuvirtide was the first marketed fusion inhibitor that worked by binding to glycoprotein 41 of the HIV envelope, preventing the conformational changes required for HIV fusion with CD4+ T cells. Due to its novel mechanisms of action, it was frequently used in the past as part of regimens for the indication of multi-class-resistant HIV until newer oral agents emerged. Here, we describe the case of a 40-year-old man who used enfuvirtide injections from 2012 to 2017 inclusive for multi-class-resistant HIV until he presented in 2021 with an abscess overlying a right lower quadrant mass requiring drainage via pigtail. Congo red stain of the tissue showed positive apple green birefringence on amorphous material after polarization, enabling the diagnosis of enfuvirtide-induced amyloidosis. The patient experienced significant improvement following surgical excision of the cysts and nodules. This case demonstrates that sequelae of injection site reactions can persist for many years following the cessation of enfuvirtide injections. |
format | Online Article Text |
id | pubmed-10483575 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-104835752023-09-08 A Blast From the Past: Abdominal Wall Amyloidosis Due to Enfuvirtide Injections Costiniuk, Cecilia Bourgault, Anne-Marie Maedler-Kron, Chelsea Feldman, Liane Cureus Internal Medicine Enfuvirtide was the first marketed fusion inhibitor that worked by binding to glycoprotein 41 of the HIV envelope, preventing the conformational changes required for HIV fusion with CD4+ T cells. Due to its novel mechanisms of action, it was frequently used in the past as part of regimens for the indication of multi-class-resistant HIV until newer oral agents emerged. Here, we describe the case of a 40-year-old man who used enfuvirtide injections from 2012 to 2017 inclusive for multi-class-resistant HIV until he presented in 2021 with an abscess overlying a right lower quadrant mass requiring drainage via pigtail. Congo red stain of the tissue showed positive apple green birefringence on amorphous material after polarization, enabling the diagnosis of enfuvirtide-induced amyloidosis. The patient experienced significant improvement following surgical excision of the cysts and nodules. This case demonstrates that sequelae of injection site reactions can persist for many years following the cessation of enfuvirtide injections. Cureus 2023-08-08 /pmc/articles/PMC10483575/ /pubmed/37692653 http://dx.doi.org/10.7759/cureus.43126 Text en Copyright © 2023, Costiniuk et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Internal Medicine Costiniuk, Cecilia Bourgault, Anne-Marie Maedler-Kron, Chelsea Feldman, Liane A Blast From the Past: Abdominal Wall Amyloidosis Due to Enfuvirtide Injections |
title | A Blast From the Past: Abdominal Wall Amyloidosis Due to Enfuvirtide Injections |
title_full | A Blast From the Past: Abdominal Wall Amyloidosis Due to Enfuvirtide Injections |
title_fullStr | A Blast From the Past: Abdominal Wall Amyloidosis Due to Enfuvirtide Injections |
title_full_unstemmed | A Blast From the Past: Abdominal Wall Amyloidosis Due to Enfuvirtide Injections |
title_short | A Blast From the Past: Abdominal Wall Amyloidosis Due to Enfuvirtide Injections |
title_sort | blast from the past: abdominal wall amyloidosis due to enfuvirtide injections |
topic | Internal Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483575/ https://www.ncbi.nlm.nih.gov/pubmed/37692653 http://dx.doi.org/10.7759/cureus.43126 |
work_keys_str_mv | AT costiniukcecilia ablastfromthepastabdominalwallamyloidosisduetoenfuvirtideinjections AT bourgaultannemarie ablastfromthepastabdominalwallamyloidosisduetoenfuvirtideinjections AT maedlerkronchelsea ablastfromthepastabdominalwallamyloidosisduetoenfuvirtideinjections AT feldmanliane ablastfromthepastabdominalwallamyloidosisduetoenfuvirtideinjections AT costiniukcecilia blastfromthepastabdominalwallamyloidosisduetoenfuvirtideinjections AT bourgaultannemarie blastfromthepastabdominalwallamyloidosisduetoenfuvirtideinjections AT maedlerkronchelsea blastfromthepastabdominalwallamyloidosisduetoenfuvirtideinjections AT feldmanliane blastfromthepastabdominalwallamyloidosisduetoenfuvirtideinjections |